A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
JUPITER, FL / ACCESSWIRE / September 14, 2020 / Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ:DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1 gene expression platform to accelerate...
Entered into two new collaborations with top tier animal health companies Entered into a fully funded human health collaboration with a top five global pharmaceutical company Started an animal trial for SARS-CoV-2 RBD vaccine candidate in Israel and another animal...
JUPITER, FL / ACCESSWIRE / July 30, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and...
JUPITER, FL / ACCESSWIRE / July 15, 2020 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate the...
Dyadic Now Partnered with all of the Top Four Animal Health Companies Five Fully Funded Animal Health Research Projects with Three New Relationships Announced this Year JUPITER, FL / ACCESSWIRE / July 8, 2020 / Dyadic International, Inc. ("Dyadic", "we", "us", "our",...
JUPITER, FL / ACCESSWIRE / June 29, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and...
JUPITER, FL / ACCESSWIRE / June 10, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower...
Two fully funded research projects with top four animal health companies. Nonexclusive research license agreement with WuXi Biologics. Feasibility study with the University of Oslo on influenza vaccine. Engineered C1 cell lines to produce high levels of potential...
JUPITER, FL / ACCESSWIRE / April 30, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and...
New research license agreement with WuXi Biologics, a leading global CDMO Two new fully funded collaborations and one expanded collaboration signed in 2020, including the third fully funded collaboration with a top tier animal health company Six funded research...
JUPITER, FL / ACCESSWIRE / March 30, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower...
NEW YORK, NY / ACCESSWIRE / March 19, 2020 / Dyadic International, Inc. (Nasdaq: DYAI) Dyadic's Chief Financial Officer Ping Rawson will be presenting at this year's New York City based Investor Summit on March 25th-26th. During the current climate of concern, The...
JUPITER, FL / ACCESSWIRE / March 18, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower...
JUPITER, FL / ACCESSWIRE / March 16, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and...
NES-ZIONA, ISRAEL and JUPITER, FL / ACCESSWIRE / February 25, 2020 / Dyadic International, Inc. (''Dyadic'') (NASDAQ:DYAI), a global biotechnology company announced today that they are joining the global fight against the coronavirus outbreak by collaborating with The...
Further Extends Company's Biologic Market Opportunities JUPITER, FL / ACCESSWIRE / February 24, 2020 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression...
JUPITER, FL / ACCESSWIRE / February 5, 2020 / Dyadic International, Inc. (the "Company") (NASDAQ:DYAI), today announced that its President and Chief Executive Officer, Mark Emalfarb, will be presenting at the following investor conferences: BIO CEO & Investor...
JUPITER, FL / ACCESSWIRE / January 31, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower...
JUPITER, FL / ACCESSWIRE / January 28, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower...
JUPITER, FL / ACCESSWIRE / January 27, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower...
Expanded ZAPI Program and Positive Preliminary Results from ZAPI Animal Study New Collaboration Agreement with Top Ten Pharmaceutical Company Expanded Research Relationship with Leading Pharmaceutical Company IIBR Collaboration Achieved Expression of Fc-fusion Enzyme...
High G0 Glycosylation Level Driving Program Acceleration JUPITER, FL / ACCESSWIRE / November 25, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression...
New Fully Funded Research Collaboration with Leading Animal Health Company; Fifth Partnership in Animal Sector Expansion of Existing Research Collaboration to Express an Additional Protein with Major Animal Health Company New Fully Funded Research Collaboration to...
JUPITER, FL / ACCESSWIRE / October 30, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to help accelerate the development, lower production...
JUPITER, FL / ACCESSWIRE / October 28, 2019 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global platform biotechnology company, announced today that it has entered into a fully funded collaboration with one of the leading animal health...
JUPITER, FL / ACCESSWIRE / October 10, 2019 / Dyadic International, Inc. (the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production...
JUPITER, FL / ACCESSWIRE / September 4, 2019 / Dyadic International, Inc. (the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production...
JUPITER, FL / ACCESSWIRE / August 21, 2019 / Dyadic International, Inc. (the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production...
New Fully Funded Research Collaboration With a Top Tier Pharmaceutical Company Expanded Technology Platform Through Multiple Collaborations and Sublicensing Agreements Robust Scientific Data Reported Up listed to the Nasdaq Capital Market and Joined Russell...
JUPITER, FL / ACCESSWIRE / July 30, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to help accelerate the development, lower production...
JUPITER, FLORIDA / ACCESSWIRE / July 5, 2019 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global platform biotechnology company, announced today that it has extended its research and development contract ("Contract") through June 2022...
JUPITER, FL / ACCESSWIRE / July 2, 2019 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate the development, lower...
JUPITER, FL / ACCESSWIRE / June 27, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs...
JUPITER, FL / ACCESSWIRE / June 11, 2019 / Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower...
JUPITER, FL / ACCESSWIRE / May 17, 2019 / Dyadic International, Inc. (the ''Company'') (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production...
Trading as DYAI on NASDAQ Capital Market as of April 17 New fully-funded proof-of-concept research collaborations with two top twenty-five pharmaceutical companies Sub-licensing agreements with Luina Bio and Alphazyme Collaboration with Serum Institute of India to...
PUNE, INDIA and JUPITER, FL / ACCESSWIRE / May 8, 2019 / Dyadic International, Inc. (''Dyadic'') (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower...
JUPITER, FL / ACCESSWIRE / May 6, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and...
JUPITER, FL / ACCESSWIRE / April 30, 2019 / Dyadic International, Inc. (''Dyadic'') (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs...
JUPITER, FL / ACCESSWIRE / April 25, 2019 / Dyadic International, Inc. ("Dyadic") (NASDAQ: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs...